JP2015528449A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015528449A5 JP2015528449A5 JP2015528817A JP2015528817A JP2015528449A5 JP 2015528449 A5 JP2015528449 A5 JP 2015528449A5 JP 2015528817 A JP2015528817 A JP 2015528817A JP 2015528817 A JP2015528817 A JP 2015528817A JP 2015528449 A5 JP2015528449 A5 JP 2015528449A5
- Authority
- JP
- Japan
- Prior art keywords
- hepatitis
- pharmaceutically acceptable
- infection
- composition
- acceptable agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003795 chemical substances by application Substances 0.000 claims description 84
- WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 claims description 3
- 229960003205 adefovir dipivoxil Drugs 0.000 claims description 3
- 230000007123 defense Effects 0.000 claims description 3
- 229960000980 entecavir Drugs 0.000 claims description 3
- YXPVEXCTPGULBZ-WQYNNSOESA-N entecavir hydrate Chemical compound O.C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)C1=C YXPVEXCTPGULBZ-WQYNNSOESA-N 0.000 claims description 3
- 229960001627 lamivudine Drugs 0.000 claims description 3
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 claims description 3
- 229960004693 tenofovir disoproxil fumarate Drugs 0.000 claims description 3
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 claims description 3
- 239000008280 blood Substances 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 208000002672 hepatitis B Diseases 0.000 claims 87
- 239000000203 mixture Substances 0.000 claims 80
- 208000005331 Hepatitis D Diseases 0.000 claims 42
- 208000003322 Coinfection Diseases 0.000 claims 39
- 108091034117 Oligonucleotide Proteins 0.000 claims 36
- 150000004697 chelate complex Chemical class 0.000 claims 21
- 229940079322 interferon Drugs 0.000 claims 15
- 108010050904 Interferons Proteins 0.000 claims 14
- 102000014150 Interferons Human genes 0.000 claims 14
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 12
- 208000006454 hepatitis Diseases 0.000 claims 12
- 231100000283 hepatitis Toxicity 0.000 claims 12
- 230000015556 catabolic process Effects 0.000 claims 10
- 238000006731 degradation reaction Methods 0.000 claims 10
- 108020004999 messenger RNA Proteins 0.000 claims 10
- 108020004707 nucleic acids Proteins 0.000 claims 10
- 102000039446 nucleic acids Human genes 0.000 claims 10
- 150000007523 nucleic acids Chemical class 0.000 claims 10
- 229920000642 polymer Polymers 0.000 claims 10
- 102100020990 Interferon lambda-1 Human genes 0.000 claims 9
- 101710099623 Interferon lambda-1 Proteins 0.000 claims 9
- 229940079593 drug Drugs 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 8
- 239000002773 nucleotide Substances 0.000 claims 8
- 125000003729 nucleotide group Chemical group 0.000 claims 8
- 101000793425 Homo sapiens Beta-2-glycoprotein 1 Proteins 0.000 claims 6
- 230000004048 modification Effects 0.000 claims 6
- 238000012986 modification Methods 0.000 claims 6
- 102000004169 proteins and genes Human genes 0.000 claims 6
- 108090000623 proteins and genes Proteins 0.000 claims 6
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 claims 5
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims 5
- 108010046075 Thymosin Proteins 0.000 claims 5
- 102000007501 Thymosin Human genes 0.000 claims 5
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 claims 5
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 claims 5
- HWPZZUQOWRWFDB-UHFFFAOYSA-N 1-methylcytosine Chemical compound CN1C=CC(N)=NC1=O HWPZZUQOWRWFDB-UHFFFAOYSA-N 0.000 claims 4
- 102100040018 Interferon alpha-2 Human genes 0.000 claims 4
- 108010079944 Interferon-alpha2b Proteins 0.000 claims 4
- 108020004459 Small interfering RNA Proteins 0.000 claims 4
- 108010078233 Thymalfasin Proteins 0.000 claims 4
- 102400000800 Thymosin alpha-1 Human genes 0.000 claims 4
- 230000000840 anti-viral effect Effects 0.000 claims 4
- 239000000074 antisense oligonucleotide Substances 0.000 claims 4
- 238000012230 antisense oligonucleotides Methods 0.000 claims 4
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims 4
- 230000003308 immunostimulating effect Effects 0.000 claims 4
- NZVYCXVTEHPMHE-ZSUJOUNUSA-N thymalfasin Chemical compound CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NZVYCXVTEHPMHE-ZSUJOUNUSA-N 0.000 claims 4
- 229960004231 thymalfasin Drugs 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 208000015181 infectious disease Diseases 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 108091023037 Aptamer Proteins 0.000 claims 2
- 108091027967 Small hairpin RNA Proteins 0.000 claims 2
- 229940123384 Toll-like receptor (TLR) agonist Drugs 0.000 claims 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 2
- 229940104302 cytosine Drugs 0.000 claims 2
- 239000005556 hormone Substances 0.000 claims 2
- 229940088597 hormone Drugs 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 150000003384 small molecules Chemical class 0.000 claims 2
- STGXGJRRAJKJRG-JDJSBBGDSA-N (3r,4r,5r)-5-(hydroxymethyl)-3-methoxyoxolane-2,4-diol Chemical compound CO[C@H]1C(O)O[C@H](CO)[C@H]1O STGXGJRRAJKJRG-JDJSBBGDSA-N 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 101001002469 Homo sapiens Interferon lambda-2 Proteins 0.000 claims 1
- 108010005716 Interferon beta-1a Proteins 0.000 claims 1
- 108010005714 Interferon beta-1b Proteins 0.000 claims 1
- 102100020989 Interferon lambda-2 Human genes 0.000 claims 1
- 108010047761 Interferon-alpha Proteins 0.000 claims 1
- 102000006992 Interferon-alpha Human genes 0.000 claims 1
- 108090000467 Interferon-beta Proteins 0.000 claims 1
- 102000003996 Interferon-beta Human genes 0.000 claims 1
- 108010074328 Interferon-gamma Proteins 0.000 claims 1
- 102000008070 Interferon-gamma Human genes 0.000 claims 1
- HOOMGTNENMZAFP-NYNCVSEMSA-N [(2r,3r,5s)-2-(5-amino-2-oxo-[1,3]thiazolo[4,5-d]pyrimidin-3-yl)-5-(hydroxymethyl)oxolan-3-yl] acetate Chemical compound CC(=O)O[C@@H]1C[C@@H](CO)O[C@H]1N1C(=O)SC2=CN=C(N)N=C21 HOOMGTNENMZAFP-NYNCVSEMSA-N 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 230000000157 blood function Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical group C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 claims 1
- 230000037406 food intake Effects 0.000 claims 1
- 229940044627 gamma-interferon Drugs 0.000 claims 1
- 230000036737 immune function Effects 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 229960004461 interferon beta-1a Drugs 0.000 claims 1
- 229960003161 interferon beta-1b Drugs 0.000 claims 1
- 108010042414 interferon gamma-1b Proteins 0.000 claims 1
- 229940028862 interferon gamma-1b Drugs 0.000 claims 1
- 238000010255 intramuscular injection Methods 0.000 claims 1
- 239000007927 intramuscular injection Substances 0.000 claims 1
- 239000007928 intraperitoneal injection Substances 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000010253 intravenous injection Methods 0.000 claims 1
- 239000002207 metabolite Substances 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 238000010254 subcutaneous injection Methods 0.000 claims 1
- 239000007929 subcutaneous injection Substances 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 210000001541 thymus gland Anatomy 0.000 claims 1
- 239000003970 toll like receptor agonist Substances 0.000 claims 1
- YWBFPKPWMSWWEA-UHFFFAOYSA-O triazolopyrimidine Chemical class BrC1=CC=CC(C=2N=C3N=CN[N+]3=C(NCC=3C=CN=CC=3)C=2)=C1 YWBFPKPWMSWWEA-UHFFFAOYSA-O 0.000 claims 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 108700024845 Hepatitis B virus P Proteins 0.000 description 1
- 229940123066 Polymerase inhibitor Drugs 0.000 description 1
- -1 Tel defenses Jin Chemical compound 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000005860 defense response to virus Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261695040P | 2012-08-30 | 2012-08-30 | |
| US61/695,040 | 2012-08-30 | ||
| US201261703816P | 2012-09-21 | 2012-09-21 | |
| US61/703,816 | 2012-09-21 | ||
| PCT/CA2013/050377 WO2014032176A1 (en) | 2012-08-30 | 2013-05-17 | Methods for the treatment of hepatitis b and hepatitis d infections |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017217194A Division JP2018039834A (ja) | 2012-08-30 | 2017-11-10 | Ｂ型肝炎感染及びｄ型肝炎感染の治療組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015528449A JP2015528449A (ja) | 2015-09-28 |
| JP2015528449A5 true JP2015528449A5 (cg-RX-API-DMAC7.html) | 2016-06-02 |
| JP6270846B2 JP6270846B2 (ja) | 2018-01-31 |
Family
ID=50182316
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015528817A Active JP6270846B2 (ja) | 2012-08-30 | 2013-05-17 | Ｂ型肝炎感染及びｄ型肝炎感染の治療方法 |
| JP2017217194A Pending JP2018039834A (ja) | 2012-08-30 | 2017-11-10 | Ｂ型肝炎感染及びｄ型肝炎感染の治療組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017217194A Pending JP2018039834A (ja) | 2012-08-30 | 2017-11-10 | Ｂ型肝炎感染及びｄ型肝炎感染の治療組成物 |
Country Status (23)
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY168778A (en) | 2012-05-18 | 2018-12-04 | Replicor Inc | Oligonucleotide chelate complex-polypeptide compositions and methods |
| TWI620568B (zh) | 2012-08-30 | 2018-04-11 | 雷普利可公司 | 用於治療ｂ型肝炎及ｄ型肝炎感染之方法 |
| MX381042B (es) | 2014-07-10 | 2025-03-12 | Replicor Inc | Uso de un complejo quelato y un anàlogo de neucleòsido o neucleòtido para tratar infecciones de virus de la hepatitis b y hepatitis d. |
| WO2016030863A1 (en) * | 2014-08-29 | 2016-03-03 | Glaxosmithkline Intellectual Property Development Limited | Compounds and methods for treating viral infections |
| US20160175245A1 (en) * | 2014-12-19 | 2016-06-23 | Mycotoxins Therapy, Llc | Treatment of diseases associated with mold and mycotoxin exposure |
| US20170016000A1 (en) | 2015-07-17 | 2017-01-19 | Arcturus Therapeutics, Inc. | Compositions and agents against hepatitis b virus and uses thereof |
| US20170137821A1 (en) | 2015-07-17 | 2017-05-18 | Arcturus Therapeutics, Inc. | Molecules and agents for treating hepatitis b virus |
| WO2017019891A2 (en) * | 2015-07-29 | 2017-02-02 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing hepatitis b virus gene expression |
| WO2017059878A1 (en) * | 2015-10-07 | 2017-04-13 | Humabs Biomed Sa | Antibodies that potently neutralize hepatitis b virus and uses thereof |
| ES3008560T3 (en) * | 2016-02-19 | 2025-03-24 | Eit Pharma Inc | Treatment of hepatitis delta virus infection with interferon lambda |
| WO2018222910A1 (en) * | 2017-05-31 | 2018-12-06 | Arbutus Biopharma Corporation | Therapeutic compositions and methods for treating hepatitis b |
| TWI815887B (zh) * | 2018-05-15 | 2023-09-21 | 美商愛彼特生物製藥股份有限公司 | 經取代的2,2'-雙嘧啶基化合物、其類似物及其使用方法 |
| KR20210033004A (ko) | 2018-07-13 | 2021-03-25 | 에프. 호프만-라 로슈 아게 | Rtel1의 발현을 조절하기 위한 올리고뉴클레오티드 |
| US11166976B2 (en) | 2018-11-08 | 2021-11-09 | Aligos Therapeutics, Inc. | S-antigen transport inhibiting oligonucleotide polymers and methods |
| JP7498714B2 (ja) | 2018-12-19 | 2024-06-12 | ヒューマブス・バイオメッド・ソシエテ・アノニム | Ｂ型肝炎ウイルスを中和する抗体およびその使用 |
| EP3897672B1 (en) | 2018-12-20 | 2023-08-09 | VIR Biotechnology, Inc. | Combination hbv therapy |
| CA3163490A1 (en) * | 2019-12-24 | 2021-07-01 | F. Hoffman-La Roche Ag | Pharmaceutical combination of a therapeutic oligonucleotide targeting hbv and a tlr7 agonist for treatment of hbv |
| CN114507663A (zh) * | 2020-11-16 | 2022-05-17 | 浙江柏拉阿图医药科技有限公司 | 寡核苷酸及其在抗乙型肝炎和丁型肝炎病毒中的应用 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6030954A (en) | 1991-09-05 | 2000-02-29 | University Of Connecticut | Targeted delivery of poly- or oligonucleotides to cells |
| US20030206887A1 (en) | 1992-05-14 | 2003-11-06 | David Morrissey | RNA interference mediated inhibition of hepatitis B virus (HBV) using short interfering nucleic acid (siNA) |
| US20040054156A1 (en) | 1992-05-14 | 2004-03-18 | Kenneth Draper | Method and reagent for inhibiting hepatitis B viral replication |
| US20040127446A1 (en) * | 1992-05-14 | 2004-07-01 | Lawrence Blatt | Oligonucleotide mediated inhibition of hepatitis B virus and hepatitis C virus replication |
| US5646262A (en) | 1994-07-28 | 1997-07-08 | Georgetown University | Antisense oligonucleotides against hepatitis B viral replication |
| IL118625A0 (en) * | 1996-06-11 | 1996-10-16 | Xtl Biopharmaceuticals Limited | Anti HBV antibodies |
| CA2254931C (en) * | 1996-06-11 | 2007-04-10 | Yeda Research And Development Co. Ltd. | Human monoclonal antibodies to the hepatitis b surface antigen |
| DE19725803C1 (de) | 1997-06-18 | 1999-02-11 | Deutsches Krebsforsch | HBV-gerichtete Antisense-Nukleinsäuren |
| IL151981A0 (en) | 2000-03-29 | 2003-04-10 | Univ Georgetown | Method of treating hepatitis delta viral infection |
| BR0314236A (pt) | 2002-09-13 | 2005-08-09 | Replicor Inc | Formulação de oligonucleotìdeo, composição farmacêutica, kit, composto antiviral, preparação de oligonucleotìdeo e métodos para seleção de um oligonucleotìdeo antiviral para uso como um agente antiviral, para profilaxia ou tratamento de uma infecção viral em um paciente, para tratamento profilático de câncer causado por oncovìrus, para identificação de um composto que altera a ligação de um oligonucleotìdeo a pelo menos um componente viral, para purificação da ligação de oligonucleotìdeos a pelo menos um componente viral e para enriquecimento de oligonucleotìdeos a partir de um agrupamento de oligonucleotìdeos |
| US20070027099A1 (en) * | 2003-05-19 | 2007-02-01 | Lin Marie C | Gene therapy of HBV infection via adeno-associated viral vector mediated long term expression of small hairpin RNA (shRNA) |
| HUE042261T2 (hu) | 2003-06-12 | 2019-06-28 | Alnylam Pharmaceuticals Inc | Gén kikapcsolásra alkalmas konzervált HBV és HCV szekvenciák |
| CN101084232A (zh) * | 2004-10-19 | 2007-12-05 | 里普利科股份有限公司 | 抗病毒寡核苷酸 |
| CN102762215A (zh) * | 2009-10-16 | 2012-10-31 | 葛兰素集团有限公司 | Hbv反义抑制剂 |
| WO2011047316A1 (en) | 2009-10-16 | 2011-04-21 | The United States Of America, As Represented By The Secretary Department Of Health And Human Services | Nucleic acid sequences encoding expandable hiv mosaic proteins |
| CA2746981A1 (en) * | 2010-08-05 | 2012-02-05 | Replicor Inc. | Methods for inhibition of apolipoprotein h |
| SG187165A1 (en) * | 2010-08-20 | 2013-02-28 | Replicor Inc | Oligonucleotide chelate complexes |
| CN103889428A (zh) | 2010-10-04 | 2014-06-25 | 肝炎与病毒研究所 | 乙型肝炎病毒抗原分泌的新型抑制剂 |
| UA118951C2 (uk) | 2011-04-21 | 2019-04-10 | Айоніс Фармасьютікалз, Інк. | Модулювання експресії вірусу гепатиту b (hbv) |
| WO2013003520A1 (en) | 2011-06-30 | 2013-01-03 | Arrowhead Research Corporation | Compositions and methods for inhibiting gene expression of hepatitis b virus |
| AR091065A1 (es) | 2012-05-18 | 2014-12-30 | Replicor Inc | Una formulacion farmaceutica que comprende un quelato de oligonucleotidos antiviral para el tratamiento de una infeccion antiviral |
| MY168778A (en) | 2012-05-18 | 2018-12-04 | Replicor Inc | Oligonucleotide chelate complex-polypeptide compositions and methods |
| TWI620568B (zh) | 2012-08-30 | 2018-04-11 | 雷普利可公司 | 用於治療ｂ型肝炎及ｄ型肝炎感染之方法 |
-
2013
- 2013-05-17 TW TW102117614A patent/TWI620568B/zh not_active IP Right Cessation
- 2013-05-17 NZ NZ705730A patent/NZ705730A/en unknown
- 2013-05-17 IN IN1087DEN2015 patent/IN2015DN01087A/en unknown
- 2013-05-17 EP EP13832690.5A patent/EP2890403A4/en not_active Withdrawn
- 2013-05-17 MY MYPI2015000437A patent/MY172785A/en unknown
- 2013-05-17 BR BR112015003985A patent/BR112015003985A2/pt not_active Application Discontinuation
- 2013-05-17 WO PCT/CA2013/050377 patent/WO2014032176A1/en not_active Ceased
- 2013-05-17 US US13/896,421 patent/US9133458B2/en active Active
- 2013-05-17 KR KR1020177032724A patent/KR102025679B1/ko not_active Expired - Fee Related
- 2013-05-17 CA CA2883785A patent/CA2883785C/en active Active
- 2013-05-17 AU AU2013308045A patent/AU2013308045B2/en active Active
- 2013-05-17 KR KR1020157007858A patent/KR20150046309A/ko not_active Ceased
- 2013-05-17 CN CN201380045796.6A patent/CN104837501B/zh active Active
- 2013-05-17 JP JP2015528817A patent/JP6270846B2/ja active Active
- 2013-05-17 MX MX2015002491A patent/MX361522B/es active IP Right Grant
- 2013-05-17 SG SG11201501255PA patent/SG11201501255PA/en unknown
-
2014
- 2014-08-01 US US14/449,173 patent/US9200283B2/en active Active
- 2014-08-01 US US14/449,174 patent/US9284556B2/en active Active
-
2015
- 2015-02-10 IL IL237173A patent/IL237173B/en active IP Right Grant
- 2015-02-18 PH PH12015500361A patent/PH12015500361B1/en unknown
- 2015-02-26 CU CUP2015000018A patent/CU20150018A7/es unknown
- 2015-02-26 DO DO2015000041A patent/DOP2015000041A/es unknown
- 2015-02-27 GT GT201500046A patent/GT201500046A/es unknown
- 2015-02-27 EC ECIEPI20157345A patent/ECSP15007345A/es unknown
- 2015-02-27 CR CR20150107A patent/CR20150107A/es unknown
- 2015-02-27 CL CL2015000499A patent/CL2015000499A1/es unknown
- 2015-09-15 US US14/854,200 patent/US9533003B2/en active Active
-
2017
- 2017-11-10 JP JP2017217194A patent/JP2018039834A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015528449A5 (cg-RX-API-DMAC7.html) | ||
| JP6922030B2 (ja) | Ｂ型肝炎およびｄ型肝炎ウイルス感染の治療のための方法 | |
| TWI620568B (zh) | 用於治療ｂ型肝炎及ｄ型肝炎感染之方法 | |
| Ma et al. | Toward a functional cure for hepatitis B: the rationale and challenges for therapeutic targeting of the B cell immune response | |
| JP2013522302A5 (cg-RX-API-DMAC7.html) | ||
| JP2009504157A5 (cg-RX-API-DMAC7.html) | ||
| WO2018087345A1 (en) | COMBINATION THERAPY OF AN HBsAg INHIBITOR, A NUCLEOS(T)IDE ANALOGUE AND AN INTERFERON | |
| JP2017521433A5 (cg-RX-API-DMAC7.html) | ||
| KR102068109B1 (ko) | 올리고뉴클레오타이드 킬레이트 복합체-폴리펩타이드 조성물 및 방법 | |
| JP2019533472A5 (cg-RX-API-DMAC7.html) | ||
| JP2015517504A5 (cg-RX-API-DMAC7.html) | ||
| EP4081216A1 (en) | Method of treating virus infection using a tlr7 agonist | |
| Stein et al. | Drug targets in hepatitis B virus infection | |
| De Clercq | Interferon and its inducers—a never-ending story:“old” and “new” data in a new perspective | |
| JPWO2020036862A5 (cg-RX-API-DMAC7.html) | ||
| Khan et al. | Developments in pharmacotherapeutic agents for hepatitis B–how close are we to a functional cure? | |
| Seto et al. | Future prevention and treatment of chronic hepatitis B infection | |
| CN114057816A (zh) | 富含腺嘌呤硫代磷酸酯化寡核苷酸及其抗肝炎病毒的应用 | |
| Deanasa et al. | The potential of antisense oligonucleotides (ASO) through inhalation based on gold nanoparticle (AuNP) delivery system in inhibiting SARS-CoV-2 replication and transcription | |
| HK40065449A (en) | Methods for the treatment of hepatitis b and hepatitis d virus infections |